My watch list  


News Taxotere

  • Hybrigenics unveils final results of inecalcitol Phase IIa clinical study in hormone-refractory prostate cancer

    Hybrigenics announced the positive outcomes of clinical tolerance Phase IIa study of daily oral inecalcitol in combination with gold standard Taxotere(R) chemotherapy in hormone-refractory prostate cancer patients. The maximal tolerated dose of inecalcitol is 4 milligrams (mg) per day and the respon more

  • Hybrigenics receives positive answers from EMEA

    Hybrigenics announced that it has received the official scientific advice from the European Medicines Agency (EMEA) on Hybrigenics' clinical development plan for inecalcitol in hormone-refractory prostate cancer patients. EMEA's recommendations back the protocol proposed by Hybrigenics and will fac more

  • Cytotoxic therapies to feel sting of generics

    Cytotoxic therapy, or chemotherapy as it is commonly known, has been the cornerstone of cancer treatment for many years and involves the use of drugs that are toxic to all cells – including those that are perfectly healthy. Whilst relatively effective, this leads to the unpleasant side effects commo more

All news on taxotere

Publications Taxotere

All publications on taxotere


This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE